{
  "docId": "019de514-f120-743f-9d00-70915b7d1fa5",
  "docSlug": "a9055659e75fd1b92a3c529616eb6953",
  "documentTitle": "Bausch+Lomb | Results Presentation Deck | 49 slides",
  "authorId": "bausch-lomb",
  "authorName": "Bausch + Lomb",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 49,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "revenue_buildup",
  "function": "decompose_segments",
  "density": "dense",
  "nDataPoints": 48,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de514-f120-743f-9d00-70915b7d1fa5/13",
  "deckHref": "/decks/019de514-f120-743f-9d00-70915b7d1fa5",
  "deckJsonHref": "/decks/019de514-f120-743f-9d00-70915b7d1fa5.json",
  "deckAnchorHref": "/decks/019de514-f120-743f-9d00-70915b7d1fa5#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.024,
        "w": 0.096,
        "x": 0.043,
        "y": 0.943
      },
      "kind": "image",
      "text": "BAUSCH+LOMB",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "946ec54d-afd7-4eb3-9cf9-fe2aaf75f7a3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.063,
        "w": 0.704,
        "x": 0.149,
        "y": 0.913
      },
      "kind": "source-note",
      "text": "1. Products with sales outside the United States impacted by F/X changes.\n2. This is a non-GAAP measure or ratio. See Slide 2 and Appendix for further information on non-GAAP measures and ratios.\n3. 4Q21 presented on an adjusted basis after giving effect to the IPO.\n4. Organic revenue growth/change, a non-GAAP measure, is defined as change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of acquisitions, divestitures and discontinuations.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ce93a33b-2d8c-4132-a970-ccdd85e901ed",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.706,
        "w": 0.847,
        "x": 0.075,
        "y": 0.164
      },
      "kind": "table",
      "text": "Bausch + Lomb 4Q22 4Q21 Reported Change Constant Currency2 Organic Change 2,4 Vision Care Revenue $626M $626M 0% 5% 5% Surgical Revenue $188M $198M (5%) 2% 4% Ophthalmic Pharmaceuticals Revenue $182M $177M 3% 7% 7% Total Revenue $996M $1,001M 0% 5% 5% Gross Profit $520M $530M (2%) 3% Gross Margin 52.2% 52.9% (70 bps) R&D $78M $70M (11%) (14%) R&D percent of Revenues 7.8% 7.0% SG&A $386M $365M (6%) (11%) SG&A percent of Revenues 38.8% 36.5% Operating Income $51M $92M (45%) (37%) Depreciation $37M $33M 12% 18% Stock Based Compensation $17M $17M 0% 0% Net (Loss) Income Attributable to Bausch + Lomb ($1M) $51M (102%) (90%) Net Income Margin (0.1%) 5.1% EPS3 Attributable to Bausch + Lomb ($0.00) $0.15",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "edfd1259-13e1-4a4e-909b-9bc2293611e8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.026,
        "w": 0.409,
        "x": 0.049,
        "y": 0.069
      },
      "kind": "title",
      "text": "Total Bausch + Lomb P&L¹ (GAAP)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dcc711fe-6d0d-4755-9f1e-7683e7bed097",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 10,
      "beatId": "7dc62337-b2ed-4c41-8d32-808d2f972bf7",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The presentation showcases the company's strong financial performance and strategic advancements, providing satisfaction to investors",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 10,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "d15671c2-99b6-48fa-89dc-6302733eef20",
      "evidence": "The presentation highlights the company's financial performance and strategic advancements, implying the consequences of not investing in Bausch + Lomb",
      "position": 0,
      "objective": "Emphasize the importance of Bausch + Lomb's solutions by highlighting the cost of inaction",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}